Caring Ambassadors Hepatitis C Program
Monthly Medical Literature Review
December
2008
In The News
Schering-Plough
to develop new oral hepatitis drug
“As part of its long-term commitment to hepatitis C therapy, Schering-Plough is
developing SCH 900518 (518), a next-generation hepatitis C virus (HCV) protease
inhibitor. A Phase IIa study with 518, known as the Next-1 study, is currently
ongoing. The company said that 518 has been shown to be 10 times more potent
in-vitro than other protease inhibitors currently in Phase III development and
has the potential for once daily dosing. The protease inhibitor also has shown
decreased emergence of resistance in vitro. Given its pharmacokinetic profile,
the company anticipates that 518 may be active against some HCV strains that
are resistant to other protease inhibitors.” Read more...
Inside-out
cells offer target for antiviral drugs
“An experimental drug cured guinea pigs infected with a fatal hemorrhagic fever
virus, raising hope for its use in a broad range of viral diseases including
influenza, hepatitis C, HIV, Ebola and others, U.S. researchers said on Sunday.
‘This is a whole new strategy for making antiviral drugs,’ said Dr. Philip
Thorpe, professor of pharmacology at the University of Texas Southwestern
Medical Center at Dallas, whose research appears in the journal Nature
Medicine.” Read more…
Indiana addresses viral hepatitis
“State
health officials say between 3.5 to 4 million Americans are living with viral
hepatitis. In 2006, there were 4,723 reported cases of chronic and acute
hepatitis C in Indiana, as well as 80 cases of hepatitis B, 33 cases of
hepatitis A, and one case of hepatitis E. To address the problem in the state,
the Indiana Viral Hepatitis Advisory Council has released ‘Indiana's Strategic
Plan for the Prevention, Care, and Elimination of Viral Hepatitis. ‘The purpose of the plan is to help our state
move forward in raising awareness of viral hepatitis, to provide additional
education and support for those living with the disease and their loved ones,
and to ultimately reduce the burden of viral hepatitis in Indiana,’ said State
Health Commissioner Judy Monroe, M.D.” Read more…
Study: Injection site saves
lives, funds
“Canada's
only supervised injection facility has extended lives of drug users and saved
the healthcare system millions of dollars, a study indicates. When examining
the cost-effectiveness of Insite, an injection facility in a Vancouver, British
Columbia, neighborhood where about 5,000 injection drug users live, University
of Western Ontario researchers said they found the facility saved about $14
million in healthcare costs and added about 920 life-years during a 10-year
period.” Read more…
FDA nixes state appeal to ban
multi-dose vials
“The head of the U.S. Food and Drug Administration has
rejected an appeal from New York State's health commissioner to ban the
manufacture of multi-dose vials, saying they are an important option for
hospitals.
In
January, state Health Commissioner Dr. Richard Daines and New York City's
health commissioner, Dr. Thomas Frieden, sent FDA Commissioner Dr. Andrew von
Eschenbach a letter calling on the FDA to eliminate the manufacture and
distribution of multi-dose vials.” Read more…
Clinical
Trials, Cohort Studies, Pilot Studies
Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Liu CH, Liu CJ, Lin CL, et al. Clin Infect Dis. 2008 Nov 15;47(10):1260-9.
Dose comparison study of pegylated interferon-alpha-2b plus ribavirin in naïve Japanese patients with hepatitis C virus genotype 2: A randomized clinical trial. Kawaoka T, Kawakami Y, Tsuji K, et al. J Gastroenterol Hepatol. 2008 Nov 19. [Epub ahead of print]
The natural history of interferon-{alpha}2b-induced thyroiditis and its exclusivity in a cohort of patients with chronic hepatitis C infection. Tran HA, Reeves GE, Jones TL. QJM. 2008 Nov 25. [Epub ahead of print]
Narcotic analgesics and progression of
fibrosis in patients with chronic hepatitis C.
Vallejos C, Bordin-Wosk T, Pockros L, Feng A, Pockros P. J Clin Gastroenterol. 2008 Nov 20. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=19034042&dopt=Abstract
The difference in the fibrosis
progression of recurrent hepatitis C after live donor liver transplantation
versus deceased donor liver transplantation is attributable to the difference
in donor age. Selzner N, Girgrah N,
Lilly L, et al. Liver Transpl. 2008 Nov
24;14(12):1778-1786.
Impact of immunosuppression without
steroids on rejection and hepatitis C virus evolution after liver
transplantation: Results of a prospective randomized study. Lladó L, Fabregat J, Castellote J, et
al. Liver Transpl. 2008 Nov
24;14(12):1752-1760. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=19025919&dopt=Abstract
Hepatitis C virus therapy in liver
transplant recipients: Response predictors, effect on fibrosis progression, and
importance of the initial stage of fibrosis.
Roche B, Sebagh M, Canfora ML, et al. Liver Transpl. 2008 Nov 24;14(12):1766-1777.
Antiviral therapy in hepatitis C virus cirrhotic patients in compensated and decompensated condition. Iacobellis A, Ippolito A, Andriulli A. World J Gastroenterol. 2008 Nov 14;14(42):6467-72.
Presence of hepatitis C virus DNA sequences in the DNA of infected patients. Zemer R, Cohen YK, Naftaly T, Klein A. Eur J Clin Invest. 2008 Nov;38(11):845-848.
Placebo-controlled trial of 400 mg amantadine combined with peginterferon alfa-2a and ribavirin for 48 weeks in chronic hepatitis C virus-1 infection. von Wagner M, Hofmann WP, Teuber G, et al. Hepatology. 2008 Nov;48(5):1404-11.
Mycophenolate mofetil monotherapy in patients who underwent liver transplantation for hepatitis C cirrhosis. Manrique A, Jiménez C, Ortega P, et al. Transplant Proc. 2008 Nov;40(9):2962-4.
Orthotopic liver transplantation for
hepatocellular carcinoma: a thirteen-year single-center experience. Castroagudín
JF, Molina E, Bustamante M, et al.
Transplant Proc. 2008 Nov;40(9):2975-7.
IL-10 promoter gene polymorphisms and sustained response to combination therapy in Taiwanese chronic hepatitis C patients. Chuang JY, Yang SS, Lu YT, et al. Dig Liver Dis. 2008 Nov 10. [Epub ahead of print]
Effects of hepatitis C virus infection
on menopause status and symptoms. Cieloszyk K, Hartel D, Moskaleva G,
Schoenbaum EE. Menopause. 2008 Nov 7. [Epub
ahead of print]
The relationship of hepatitis antibodies
and elevated liver enzymes with impaired fasting glucose and undiagnosed
diabetes
Mainous AG, Diaz VA, King DE, Everett CJ, Player MS. . J Am Board Fam Med. 2008 Nov-Dec;21(6):497-503.
Natural human interferon beta plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus and a high viral load. Katamura Y, Suzuki F, Akuta N, et al. Intern Med. 2008;47(21):1827-34.
Basic
and Applied Science, Pre-Clinical Studies
Genetic markers of IgG influence the
outcome of infection with hepatitis C virus. Pandey JP, Namboodiri AM, Luo
Y, et al. J Infect Dis. 2008 Nov
1;198(9):1334-1336. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=18855559&dopt=Abstract
Porphyria cutanea tarda, hepatitis C,
uroporphyrinogen decarboxylase and mutations of HFE Gene. A case-control study.
Cribier B, Chiaverini C, Dali-Youcef N, et al. Dermatology. 2008 Nov 12. [Epub ahead of
print]
Hepatitis C virus immune escape via exploitation of a hole in the T cell repertoire. Wölfl M, Rutebemberwa A, Mosbruger T, et al. J Immunol. 2008 Nov 1;181(9):6435-46.
Effect of interferon-alpha, ribavirin, pentoxifylline, and interleukin-18 antibody on hepatitis C sera-stimulated hepatic stellate cell proliferation. Khan F, Peltekian KM, Peterson TC. J Interferon Cytokine Res. 2008 Nov;28(11):643-51.
Expression of apolipoprotein C-IV is regulated by Ku antigen/peroxisome proliferator-activated receptor gamma complex and correlates with liver steatosis. Kim E, Li K, Lieu C, et al. J Hepatol. 2008 Nov;49(5):787-98.
Skew in T cell receptor usage with polyclonal expansion in lesions of oral lichen planus without hepatitis C virus infection. Gotoh A, Hamada Y, Shiobara N, et al. Clin Exp Immunol. 2008 Nov;154(2):192-201.
Hepatitis C virus core protein augments
androgen receptor-mediated signaling. Kanda T, Steele R, Ray R, Ray RB. J Virol. 2008 Nov;82(22):11066-72.
Evidence for protection against chronic hepatitis C virus infection in chimpanzees by immunization with replicating recombinant vaccinia virus. Youn JW, Hu YW, Tricoche N,
et al. J Virol. 2008 Nov;82(21):10896-905.
Kinetic analysis by real-time PCR of
hepatitis C virus (HCV)-specific T cells in peripheral blood and liver after
challenge with HCV. Ramalingam RK, Meyer-Olson D, Shoukry NH, Bowen DG,
Walker CM, Kalams SA. J Virol. 2008
Nov;82(21):10487-92. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=18715926&dopt=Abstract
Differential expression of the CXCR3 ligands in chronic hepatitis C, and their modulation by HCV in vitro. Helbig KJ, Ruszkiewicz A, Lanford RE, et al. J Virol. 2008 Nov 5. [Epub ahead of print]
Cyclic changes in gene expression induced by Peg-interferon alfa-2b plus ribavirin in peripheral blood monocytes (PBMC) of hepatitis C patients during the first 10 weeks of treatment. Taylor MW, Tsukahara T, McClintick JN, Edenberg HJ, Kwo P. J Transl Med. 2008 Nov 5;6(1):66. [Epub ahead of print]
Subcellular localizations of the hepatitis C virus alternate reading frame proteins. Ratinier M, Boulant S, Crussard S, McLauchlan J, Lavergne JP. Virus Res. 2008 Nov 6. [Epub ahead of print]
Helical peptides derived from lactoferrin bind hepatitis C virus envelope protein e2. Beleid R, Douglas D, Kneteman N, Kaur K. Chem Biol Drug Des. 2008 Nov;72(5):436-43.
Cellular vimentin content regulates the protein level of hepatitis C virus core protein and the hepatitis C virus production in cultured cells. Nitahara-Kasahara Y, Fukasawa M, Shinkai-Ouchi F, et al. Virology. 2008 Nov 13. [Epub ahead of print]
Heme oxygenase-1 suppresses hepatitis C virus replication and increases resistance of hepatocytes to oxidant injury. Zhu Z, Wilson AT, Mathahs MM, et al. Hepatology. 2008 Nov;48(5):1430-9.
Fatty acid synthase is up-regulated during hepatitis C virus infection and regulates hepatitis C virus entry and production. Yang W, Hood BL, Chadwick SL, et al. Hepatology. 2008 Nov;48(5):1396-403.
Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C. Zeremski M, Petrovic LM, Chiriboga L, et al. Hepatology. 2008 Nov;48(5):1440-50.
Clinical relevance of the 2'-5'-oligoadenylate synthetase/RNase L system for treatment response in chronic hepatitis C. Mihm U, Ackermann O, Welsch C, et al. J Hepatol. 2008 Nov 11. [Epub ahead of print]
Role of molecular mimickry of hepatitis C-virus (HCV) protein with platelet GPIIIa in hepatitis C-related immunologic thrombocytopenia. Zhang W, Nardi MA, Li Z, Borkowsky W, Karpatkin S. Blood. 2008 Nov 20. [Epub ahead of print]
EWI-2wint - A host cell factor
inhibiting hepatitis C virus entry. Schuster C, Baumert TF. J Hepatol. 2008 Nov 5; [Epub ahead of print]
Interferon-alpha therapy does not
modulate hepatic expression of classical type I interferon inducible genes. Meier
V, Mihm S, Ramadori G, et al. J Med
Virol. 2008 Nov;80(11):1912-8.
HIV/HCV
Coinfection
Increase in serum bilirubin in HIV/hepatitis-C virus-coinfected patients on atazanavir therapy following initiation of pegylated-interferon and ribavirin. Rodríguez-Nóvoa S, Morello J, González M, et al. AIDS. 2008 Nov 30;22(18):2535-7.
Diagnosing acute hepatitis C in HIV-infected patients: Nucleic acid testing compared with antibody and antigen-antibody detecting methods. Nastouli E, Thomson EC, Karayiannis P, Main J, McClure M, Muir D. J Clin Virol. 2008 Nov 3. [Epub ahead of print]
Role of pegylated interferon-alpha-2a
and ribavirin concentrations in sustained viral response in HCV/HIV-coinfected
patients. Lopez-Cortes LF,
Valera-Bestard B, Gutierrez-Valencia A, et al.
Clin Pharmacol Ther. 2008 Nov;84(5):573-80.
Complementary
& Alternative Therapy
Treatment with silybin-vitamin E-phospholipid complex in patients with hepatitis C infection. Falasca K, Ucciferri C, Mancino P, et al. J Med Virol. 2008 Nov;80(11):1900-6.
Epidemiology, Diagnostics, and Miscellaneous
Works
An evidence synthesis approach to
estimating Hepatitis C Prevalence in England and Wales. De Angelis D,
Sweeting M, Ades AE, Hickman M, Hope V, Ramsay M. Stat methods Med Res. 2008
Nov 26. [Epub ahead of print]
Estimating current injectors in Scotland and their drug-related death rate by sex, region and age-group via Bayesian capture-recapture methods. King R, Bird S, Hay G, Hutchinson S. Stat methods Med Res. 2008 Nov 26. [Epub ahead of print]
Modelling and
calibration of the hepatitis C epidemic in Australia. Razali K, Amin J,
Dore GJ, Law MG. World J Gastroenterol. 2008 Nov 21;14(43):6689-93.
http://www.ncbi.nlm.nih.gov/pubmed/19036911?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum
Co-infection of hepatitis B and hepatitis C virus in human immunodeficiency virus-infected patients in New York City, United States. Kim JH, Psevdos G, Suh J, Sharp VL.World J Gastroenterol. 2008 Nov 21;14(43):6689-93.
Treating hepatitis C
in the prison population is cost-saving. Tan JA, Joseph TA, Saab S. Hepatology. 2008 Nov;48(5):1387-95.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=18924228&dopt=Abstract
Seroprevalence of
select bloodborne pathogens and associated risk behaviors among injection drug
users in the Paso del Norte region of the United States - Mexico border. Baumbach
JP, Foster LN, Mueller M, et al. Harm Reduct J. 2008 Nov 16;5(1):33.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=19014605&dopt=Abstract
Chronic viral hepatitis may diminish the
gains of HIV antiretroviral therapy in sub-Saharan Africa. Cooper CL, Mills
E, Wabwire BO, Ford N, Olupot-Olupot P.
Int J Infect Dis. 2008 Nov 10. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=19004656&dopt=Abstract
Single-cell-based image analysis of
high-throughput cell array screens for quantification of viral infection. Matula
P, Kumar A, Wörz I, et al. Cytometry A.
2008 Nov 11. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=19006066&dopt=Abstract
Effect of race and HIV co-infection upon
treatment prescription for hepatitis C virus. Butt AA, Tsevat J, Leonard AC, et al. Int J Infect Dis. 2008 Nov 5. [Epub ahead of
print]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=18993100&dopt=Abstract
Host- rather than virus-related factors
reduce health-related quality of life in hepatitis C virus infection. Helbling
B, Overbeck K, Gonvers JJ, et al. Gut.
2008 Nov;57(11):1597-603. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=18625696&dopt=Abstract
Whole blood as an alternative to plasma
for detection of hepatitis C virus RNA.
Daniel HD, David J, Grant PR, Garson JA, Chandy GM, Abraham P. J Clin
Microbiol. 2008 Nov;46(11):3791-4.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=18701664&dopt=Abstract
Evaluation and improvement of a reliable diagnosis of cirrhosis by blood tests. Calès P, Boursier J, de Lédinghen V, et al. Gastroenterol Clin Biol. 2008 Nov 17. [Epub ahead of print]